Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy
Sewanti Limaye(Dana-Farber Cancer Institute), Barbara A. Murphy(Vanderbilt University), Michael T. Brennan, Fiona Cilli(ActoGeniX (Belgium)), Robert I. Haddad(Georgetown University), Kenneth S. Hu(Mount Sinai Beth Israel), A. Dimitrios Colevas(Cancer Institute (WIA)), Stephen T. Sonis(Brigham and Women's Hospital)
Cited by 126
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926